NCT03577171View on ClinicalTrials.gov

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

June 21, 2019

Study Completion Date

June 21, 2019

Conditions
Chronic Hepatitis B
Interventions
DRUG

ABI-H0731

Participants will receive 300mg QD of ABI-H0731 tablets orally.

DRUG

SOC ETV

Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.

DRUG

Placebo Oral Tablet

Participants will receive matching QD placebo tablets orally.

Trial Locations (12)

10016

NYU Langone Health, New York

19107

Xiaoli Ma MD, Philadelphia

21287

Johns Hopkins University School of Medicine, Baltimore

90057

Asia Pacific Liver Center, Los Angeles

92105

Research and Education, San Diego

92118

Southern California Research Center, Coronado

94115

Quest Clinical Research, San Francisco

V6Z 2K5

GI Research Institute, Vancouver

M6H 3M1

Toronto Liver Center, Toronto

Unknown

University of Hong Kong, Queen Mary Hospital, Hong Kong

Waikato Hospital, Hamilton

King's College London, London

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY

NCT03577171 - A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) | Biotech Hunter | Biotech Hunter